Lutetium (177Lu) chloride

Lutetium (177Lu) chloride, sold under the brand name Lumark among others, is a radioactive compound used for radiolabeling other medicines.[1][2] It is an isotopomer of lutetium(III) chloride containing the radioactive isotope 177Lu, which undergoes beta decay with a half-life of 6.65 days.

Lutetium (177Lu) chloride
Clinical data
Trade namesLumark, EndolucinBeta
AHFS/Drugs.comLumark UK Drug Information
EndolucinBeta UK Drug Information
License data
ATC code
  • none
Legal status
Legal status
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaCl3Lu
Molar mass281.32 g·mol−1
3D model (JSmol)

The most common side effects are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), lymphopenia (low levels of lymphocytes, a particular type of white blood cell), nausea (feeling sick), vomiting and mild and temporary hair loss.[1]

Medical uses

Lutetium (177Lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients.[1] It is to be used only for the radiolabeling of carrier molecules that have been specifically developed and authorised for radiolabeling with Lutetium (177Lu) chloride.[1]

Contraindications

Medicines radiolabeled with lutetium (177Lu) chloride must not be used in women unless pregnancy has been ruled out.[1]

History

Lutetium (177Lu) chloride (Lumark) was approved for use in the European Union in June 2015.[1] Lutetium (177Lu) chloride (EndolucinBeta) was approved for use in the European Union in July 2016.[2]

References
  1. "Lumark EPAR". European Medicines Agency. Retrieved 7 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. "EndolucinBeta EPAR". European Medicines Agency (EMA). Retrieved 7 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.